These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34166980)

  • 1. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
    Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
    EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
    Chen J; Mu Q; Li X; Yin X; Yu M; Jin J; Li C; Zhou Y; Zhou J; Suo S; Lu D; Jin J
    Oncotarget; 2017 Jun; 8(25):40318-40326. PubMed ID: 28454099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
    Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
    Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis.
    Qiu Y; Bai L; Zhao H; Mei X
    BMC Cancer; 2024 Apr; 24(1):520. PubMed ID: 38658865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
    Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
    Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
    Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
    J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway.
    Bai Y; Liu X; Qi X; Liu X; Peng F; Li H; Fu H; Pei S; Chen L; Chi X; Zhang L; Zhu X; Song Y; Wang Y; Meng S; Jiang T; Shao S
    EBioMedicine; 2019 Apr; 42():311-325. PubMed ID: 30922965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
    Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.
    Li F; Ling Q; Lian J; Chen Y; Hu C; Yang M; Zhang X; Li C; Mao S; Ye W; Li X; Lin X; Wei W; Huang X; Pan J; Qian Y; Wang J; Lu Y; Jin J
    Cancer Med; 2023 Apr; 12(7):8319-8330. PubMed ID: 36621846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
    Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
    Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPO1 is a new target of homoharringtonine (HHT): Making NPMc
    Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
    Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
    Yuan F; Li D; Li G; Cheng C; Wei X
    Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy.
    Shang J; Chen WM; Liu S; Wang ZH; Wei TN; Chen ZZ; Wu WB
    Leuk Res; 2019 Oct; 85():106198. PubMed ID: 31401408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
    Li X; Li C; Jin J; Wang J; Huang J; Ma Z; Huang X; He X; Zhou Y; Xu Y; Yu M; Huang S; Yan X; Li F; Pan J; Wang Y; Yu Y; Jin J
    EBioMedicine; 2018 Dec; 38():47-56. PubMed ID: 30472087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homoharringtonine deregulates
    Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells.
    Li D; Yu Z; Wang T; Li Y; Chen X; Wu L
    Exp Cell Res; 2020 Jun; 391(2):111985. PubMed ID: 32259522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.
    Pang Y; Zhao Y; Wang Y; Wang X; Wang R; Liu N; Li P; Ji M; Ye J; Sun T; Li J; Ma D; Lu F; Ji C
    J Exp Clin Cancer Res; 2020 Aug; 39(1):158. PubMed ID: 32795319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.